How’s work been for you? I’m still gainfully employed, watching tens of thousands of other devs getting laid off… It’s sad, but I think that we’re entering into an enlightenment period for humanity.. money & work will change, that’s for sure… #jobmarket#unemployed
Future conflict is guaranteed.
This is what you should do:
1) collect as many dollars as possible
2) trade your dollars for things that will help during the chaos
3) live your life
Seeking fearless female content creator with unfiltered, differentiated voice willing to move to Austin and build the next great podcast alongside a world class team.
If you know one, send her my way.
$MRNA $CLX on high watch
Didn’t realize Clorox owns Purell now which is a big deal.
This potential pandemic might get more out of control than people think, and in order to gain exposure to it, the plays above are nice way to trade it.
Everyone’s buying Nvidia.
Smart money is buying what Nvidia’s chips can’t exist without.
Here’s the physical layer underneath AI that nobody’s talking about 🧵
Sign up with my invite code & start your moomoo brokerage journey to snag awesome welcome rewards!
Use my code & get:
- 8.1% APY* on uninvested cash
- Up to $1,000 NVDA stock
https://t.co/dYTom3j4ui
#moomoo#stock#invest#US
🚀 Something exciting is coming to the creator economy.
No noise.
No fake hype.
Just a smarter way for communities, creators, and culture to grow together.
✨ Early access is now open for Rally
Join the waitlist before everyone else catches on.
🔗 https://t.co/Yy2KkUo90n
Update on $GERN — earnings just dropped and it was a beat. Q1 revenue came in at $51.8M, well above the ~$50-52M consensus, and EPS loss of just $0.01 vs. the expected -$0.03. Prescribing accounts up 12% QoQ, now at 1,450.
Just picked up some $GERN ahead of tomorrow's Q1 earnings (pre-market, 8am ET). The thesis: stock is beaten down near 52-week lows after a rough February earnings miss, but the core story is intact.
The real prize is the IMpactMF Phase 3 myelofibrosis trial — interim data is expected imminently, and Phase 2 showed nearly double the survival vs. historical controls. At ~$1.53 with $400M+ in cash on the balance sheet, the downside feels more limited than the upside. DYOR.